Long-chain omega-3 fatty acids: Time to establish a dietary reference intake

Nutrition Reviews

Volumn 71, Issue 10, 2013, Pages 692-707

  Flock, Michael R ^a   Harris, William S ^b,c   Kris Etherton, Penny M ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

^c Health Diagnostic Laboratory Inc   (United States)

Author keywords

Cardiovascular disease; DHA; Dietary reference intakes; EPA; Omega 3 fatty acids

Indexed keywords

CALCIUM; CARBOHYDRATE; CYTOCHROME P450; DOCOSAHEXAENOIC ACID; ESSENTIAL FATTY ACID; FISH OIL; G PROTEIN COUPLED RECEPTOR; HIGH DENSITY LIPOPROTEIN; ICOSANOID; ICOSAPENTAENOIC ACID; LONG CHAIN FATTY ACID; LOW DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; VITAMIN D;

ACUTE CORONARY SYNDROME; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN DEVELOPMENT; CHRONIC DISEASE; COGNITION; DIET SUPPLEMENTATION; DIETARY FIBER; DIETARY INTAKE; DIETARY REFERENCE INTAKE; ENERGY; EXECUTIVE FUNCTION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; MACRONUTRIENT; MEMBRANE FLUIDITY; META ANALYSIS (TOPIC); MILD COGNITIVE IMPAIRMENT; PHOSPHOLIPID BILAYER; PREGNANT WOMAN; PRIMARY PREVENTION; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SAFETY; SEA FOOD; SECONDARY PREVENTION; SEX DIFFERENCE; SUDDEN CARDIAC DEATH; SYSTEMATIC REVIEW (TOPIC); TRIACYLGLYCEROL BLOOD LEVEL; WORKING MEMORY;

CARDIOVASCULAR DISEASE; DHA; DIETARY REFERENCE INTAKES; EPA; OMEGA-3 FATTY ACIDS;

CARDIOVASCULAR DISEASES; DIET; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; HUMANS; NUTRITIONAL REQUIREMENTS; RECOMMENDED DIETARY ALLOWANCES; UNITED STATES;

EID: 84885468015     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/nure.12071     Document Type: Article

References (187)

1. Zhang MJ, Spite M. Resolvins: anti-inflammatory and proresolving mediators derived from omega-3 polyunsaturated fatty acids. Annu Rev Nutr. 2012;33:203-227.
2. Adkins Y, Kelley DS. Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J Nutr Biochem. 2010;21:781-792.
3. Kris-Etherton PM, Harris WS, Appel LJ. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol. 2003;23:151-152.
4. Trikalinos TA, Lee J, Moorthy D, etal. Effects of Eicosapentanoic Acid and Docosahexanoic Acid on Mortality Across Diverse Settings: Systematic Review and Meta-Analysis of Randomized Trials and Prospective Cohorts: Nutritional Research Series, Vol. 4. 2012. Rockville, MD: Agency for Healthcare Research and Quality. Publication 12-EHC040-E.
5. US Department of Agriculture and US Department of Health and Human Services. Dietary Guidelines for Americans, 2010. 7th ed. Washington, DC: US Government Printing Office; 2010.
6. Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients). Washington, DC: The National Academies Press; 2005.
7. Kris-Etherton PM, Grieger JA, Etherton TD. Dietary reference intakes for DHA and EPA. Prostaglandins Leukot Essent Fatty Acids. 2009;81:99-104.
8. Ross AC, Manson JE, Abrams SA, etal. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53-58.
9. Brenna JT. Efficiency of conversion of alpha-linolenic acid to long chain n-3 fatty acids in man. Curr Opin Clin Nutr Metab Care. 2002;5:127-132.
10. Plourde M, Cunnane SC. Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. Appl Physiol Nutr Metab. 2007;32:619-634.
11. Burdge GC, Wootton SA. Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. Br J Nutr. 2002;88:411-420.
12. Burdge GC, Calder PC. Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reprod Nutr Dev. 2005;45:581-597.
13. Williams CM, Burdge G. Long-chain n-3 PUFA: plant v. marine sources. Proc Nutr Soc. 2006;65:42-50.
14. Kris-Etherton PM, Innis S, American Dietetic Association, et al. Position of the American Dietetic Association and Dietitians of Canada: dietary fatty acids. J Am Diet Assoc. 2007;107:1599-1611.
15. Simopoulos AP, Leaf A, Salem N Jr. Workshop statement on the essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2000;63:119-121.
16. European Food Safety Authority Panel on Dietetic Products, Nutrition, and Allergies (NDA). Scientific Opinion of the Panel on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA J. 2010;8:1461.
17. Food and Agriculture Organization/World Health Organization. Fats and fatty acids in human nutrition. Proceedings of the Joint FAO/WHO Expert Consultation. November 10-14, 2008. Geneva, Switzerland. Ann Nutr Metab. 2009;55:5-300.
18. Musa-Veloso K, Binns MA, Kocenas A, etal. Impact of low v. moderate intakes of long-chain n-3 fatty acids on risk of coronary heart disease. Br J Nutr. 2011;106:1129-1141.
19. Harris WS, Kris-Etherton PM, Harris KA. Intakes of long-chain omega-3 fatty acid associated with reduced risk for death from coronary heart disease in healthy adults. Curr Atheroscler Rep. 2008;10:503-509.
20. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747-2757.
21. Harris WS, Pottala JV, Sands SA, etal. Comparison of the effects of fish and fish-oil capsules on the n-3 fatty acid content of blood cells and plasma phospholipids. Am J Clin Nutr. 2007;86:1621-1625.
22. Lloyd-Jones DM, Hong Y, Labarthe D, etal. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation. 2010;121:586-613.
23. Harris WS. Expert opinion: omega-3 fatty acids and bleeding - cause for concern? Am J Cardiol. 2007;99(Suppl 1):S44-S46.
24. European Food Safety Authority. Scientific Opinion on the Tolerable Upper Intake Level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA J. 2012;10:2815-2882.
25. Judge MP, Harel O, Lammi-Keefe CJ. Maternal consumption of a docosahexaenoic acid-containing functional food during pregnancy: benefit for infant performance on problem-solving but not on recognition memory tasks at age 9mo. Am J Clin Nutr. 2007;85:1572-1577.
26. Dunstan JA, Simmer K, Dixon G, etal. Cognitive assessment of children at age 2(1/2) years after maternal fish oil supplementation in pregnancy: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2008;93:F45-F50.
27. Anderson P, Doyle LW. Neurobehavioral outcomes of school-age children born extremely low birth weight or very preterm in the 1990s. JAMA. 2003;289:3264-3272.
28. Birch EE, Garfield S, Hoffman DR, etal. A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants. Dev Med Child Neurol. 2000;42:174-181.
29. Campoy C, Escolano-Margarit MV, Anjos T, etal. Omega 3 fatty acids on child growth, visual acuity and neurodevelopment. Br J Nutr. 2012;107(Suppl 2):S85-S106.
30. US Department of Agriculture. Nutrient intakes from food: mean amounts consumed per individual, by gender and age, in the United States, 2009-2010. In: What We Eat in America, NHANES 2009-2012. Washington, DC: Agricultural Research Service; 2012.
31. Bucher HC, Hengstler P, Schindler C, etal. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002;112:298-304.
32. Dolecek TA. Epidemiological evidence of relationships between dietary polyunsaturated fatty acids and mortality in the Multiple Risk Factor Intervention Trial. Proc Soc Exp Biol Med. 1992;200:177-182.
33. Hu FB, Cho E, Rexrode KM, etal. Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation. 2003;107:1852-1857.
34. Erkkila AT, Lehto S, Pyorala K, etal. n-3 Fatty acids and 5-y risks of death and cardiovascular disease events in patients with coronary artery disease. Am J Clin Nutr. 2003;78:65-71.
35. He K, Liu K, Daviglus ML, etal. Intakes of long-chain n-3 polyunsaturated fatty acids and fish in relation to measurements of subclinical atherosclerosis. Am J Clin Nutr. 2008;88:1111-1118.
36. Nagata C, Takatsuka N, Shimizu H. Soy and fish oil intake and mortality in a Japanese community. Am J Epidemiol. 2002;156:824-831.
37. Siscovick DS, Raghunathan TE, King I, etal. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA. 1995;274:1363-1367.
38. Djousse L, Akinkuolie AO, Wu JH, etal. Fish consumption, omega-3 fatty acids and risk of heart failure: a meta-analysis. Clin Nutr. 2012;31:846-853.
39. Khawaja O, Gaziano JM, Djousse L. A meta-analysis of omega-3 fatty acids and incidence of atrial fibrillation. J Am Coll Nutr. 2012;31:4-13.
40. Mozaffarian D, Wu JH, de Oliveira Otto MC, etal. Fish oil and post-operative atrial fibrillation - a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2013;61:2194-2196.
41. Rizos EC, Ntzani EE, Bika E, etal. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308:1024-1033.
42. Kwak SM, Myung SK, Lee YJ, etal. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med. 2012;172:686-694.
43. Filion KB, El Khoury F, Bielinski M, etal. Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2010;10:24.
44. Hooper L, Thompson RL, Harrison RA, etal. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev. 2004;(4):CD003177.
45. Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol. 2009;32:365-372.
46. Leon H, Shibata MC, Sivakumaran S, etal. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ. 2008;337:a2931.
47. Burr ML, Fehily AM, Gilbert JF, etal. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet. 1989;334:757-761.
48. Sacks FM, Stone PH, Gibson CM, etal. Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group. J Am Coll Cardiol. 1995;25:1492-1498.
49. Singh RB, Niaz MA, Sharma JP, etal. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian Experiment of Infarct Survival-4. Cardiovasc Drugs Ther. 1997;11:485-491.
50. Leng GC, Lee AJ, Fowkes FG, etal. Randomized controlled trial of gamma-linolenic acid and eicosapentaenoic acid in peripheral arterial disease. Clin Nutr. 1998;17:265-271.
51. von Schacky C, Angerer P, Kothny W, etal. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;130:554-562.
52. Johansen O, Seljeflot I, Hostmark AT, etal. The effect of supplementation with omega-3 fatty acids on soluble markers of endothelial function in patients with coronary heart disease. Arterioscler Thromb Vasc Biol. 1999;19:1681-1686.
53. Durrington PN, Bhatnagar D, Mackness MI, etal. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart. 2001;85:544-548.
54. Nilsen DW, Albrektsen G, Landmark K, etal. Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. Am J Clin Nutr. 2001;74:50-56.
55. Marchioli R, Barzi F, Bomba E, etal. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105:1897-1903.
56. Burr ML, Ashfield-Watt PA, Dunstan FD, etal. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr. 2003;57:193-200.
57. Leaf A, Albert CM, Josephson M, etal. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation. 2005;112:2762-2768.
58. Raitt MH, Connor WE, Morris C, etal. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA. 2005;293:2884-2891.
59. Brouwer IA, Zock PL, Camm AJ, etal. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty acids and ventricular Arrhythmia (SOFA) randomized trial. JAMA. 2006;295:2613-2619.
60. Yokoyama M, Origasa H, Matsuzaki M, etal. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090-1098.
61. Tavazzi L, Maggioni AP, Marchioli R, etal. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223-1230.
62. Rauch B, Schiele R, Schneider S, etal. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122:2152-2159.
63. Galan P, Kesse-Guyot E, Czernichow S, etal. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010;341:c6273.
64. Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363:2015-2026.
65. Einvik G, Klemsdal TO, Sandvik L, etal. A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk. Eur J Cardiovasc Prev Rehabil. 2010;17:588-592.
66. Bosch J, Gerstein HC, Dagenais GR, etal. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309-318.
67. Chowdhury R, Stevens S, Gorman D, etal. Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis. BMJ. 2012;345:e6698.
68. US Food and Drug Administration. Letter regarding dietary supplement health claim for omega-3 fatty acids and coronary heart disease. October 31, 2000. Docket no. 91N-0103. Washington, DC: USDA; 2000.
69. Froyland L, Bentsen H, Graff IE, etal. Evaluation of negative and positive health effects of n-3 fatty acids as constituents of food supplements and fortified foods. Oslo: Steering Committee of the Norwegian Scientific Committee for Food Safety; 2011.
70. Harris WS, Mozaffarian D, Lefevre M, etal. Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids. J Nutr. 2009;139:S804-S819.
71. Stevenson WG, Stevenson LW, Middlekauff HR, etal. Sudden death prevention in patients with advanced ventricular dysfunction. Circulation. 1993;88:2953-2961.
72. Campbell RW, Murray A, Julian DG. Ventricular arrhythmias in first 12 hours of acute myocardial infarction. Natural history study. Br Heart J. 1981;46:351-357.
73. Leaf A, Kang JX, Xiao YF, etal. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation. 2003;107:2646-2652.
74. Billman GE, Kang JX, Leaf A. Prevention of sudden cardiac death by dietary pure omega-3 polyunsaturated fatty acids in dogs. Circulation. 1999;99:2452-2457.
75. Christensen JH, Riahi S, Schmidt EB, etal. n-3 Fatty acids and ventricular arrhythmias in patients with ischaemic heart disease and implantable cardioverter defibrillators. Europace. 2005;7:338-344.
76. Schrepf R, Limmert T, Claus Weber P, etal. Immediate effects of n-3 fatty acid infusion on the induction of sustained ventricular tachycardia. Lancet. 2004;363:1441-1442.
77. Thies F, Garry JM, Yaqoob P, etal. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet. 2003;361:477-485.
78. Roche HM, Gibney MJ. Postprandial triacylglycerolaemia: the effect of low-fat dietary treatment with and without fish oil supplementation. Eur J Clin Nutr. 1996;50:617-624.
79. Nestel PJ. Fish oil and cardiovascular disease: lipids and arterial function. Am J Clin Nutr. 2000;71(Suppl 1):S228-S231.
80. Eslick GD, Howe PR, Smith C, etal. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol. 2009;136:4-16.
81. Hartweg J, Farmer AJ, Perera R, etal. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia. 2007;50:1593-1602.
82. Geleijnse JM, Giltay EJ, Grobbee DE, etal. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens. 2002;20:1493-1499.
83. Shimokawa H, Vanhoutte PM. Dietary omega 3 fatty acids and endothelium-dependent relaxations in porcine coronary arteries. Am J Physiol. 1989;256(4 Pt 2):H968-H973.
84. Yin K, Chu ZM, Beilin LJ. Blood pressure and vascular reactivity changes in spontaneously hypertensive rats fed fish oil. Br J Pharmacol. 1991;102:991-997.
85. Chu ZM, Yin K, Beilin LJ. Fish oil feeding selectively attenuates contractile responses to noradrenaline and electrical stimulation in the perfused mesenteric resistance vessels of spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1992;19:177-181.
86. McVeigh GE, Brennan GM, Cohn JN, etal. Fish oil improves arterial compliance in non-insulin-dependent diabetes mellitus. Arterioscler Thromb. 1994;14:1425-1429.
87. Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep. 2004;6:461-467.
88. Calder PC. n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci (Lond). 2004;107:1-11.
89. Goodnight SH, Jr, Harris WS, Connor WE. The effects of dietary omega 3 fatty acids on platelet composition and function in man: a prospective, controlled study. Blood. 1981;58:880-885.
90. Sanders TA, Vickers M, Haines AP. Effect on blood lipids and haemostasis of a supplement of cod-liver oil, rich in eicosapentaenoic and docosahexaenoic acids, in healthy young men. Clin Sci (Lond). 1981;61:317-324.
91. von Schacky C, Fischer S, Weber PC. Long-term effects of dietary marine omega-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans. J Clin Invest. 1985;76:1626-1631.
92. Calzada C, Colas R, Guillot N, etal. Subgram daily supplementation with docosahexaenoic acid protects low-density lipoproteins from oxidation in healthy men. Atherosclerosis. 2010;208:467-472.
93. Baumann KH, Hessel F, Larass I, etal. Dietary omega-3, omega-6, and omega-9 unsaturated fatty acids and growth factor and cytokine gene expression in unstimulated and stimulated monocytes. A randomized volunteer study. Arterioscler Thromb Vasc Biol. 1999;19:59-66.
94. Finstad HS, Drevon CA, Kulseth MA, etal. Cell proliferation, apoptosis and accumulation of lipid droplets in U937-1 cells incubated with eicosapentaenoic acid. Biochem J. 1998;336(Pt 2):451-459.
95. Lopez-Garcia E, Schulze MB, Manson JE, etal. Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. J Nutr. 2004;134:1806-1811.
96. Richard D, Kefi K, Barbe U, etal. Polyunsaturated fatty acids as antioxidants. Pharmacol Res. 2008;57:451-455.
97. Zampelas A, Panagiotakos DB, Pitsavos C, etal. Fish consumption among healthy adults is associated with decreased levels of inflammatory markers related to cardiovascular disease: the ATTICA study. J Am Coll Cardiol. 2005;46:120-124.
98. Zhao G, Etherton TD, Martin KR, etal. Anti-inflammatory effects of polyunsaturated fatty acids in THP-1 cells. Biochem Biophys Res Commun. 2005;336:909-917.
99. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006;296:1885-1899.
100. Musa-Veloso K, Binns MA, Kocenas AC, etal. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides. Nutr Rev. 2010;68:155-167.
101. Harris WS, Connor WE, Illingworth DR, etal. Effects of fish oil on VLDL triglyceride kinetics in humans. J Lipid Res. 1990;31:1549-1558.
102. Nestel PJ, Connor WE, Reardon MF, etal. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest. 1984;74:82-89.
103. Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res. 2003;44:455-463.
104. Oh DY, Talukdar S, Bae EJ, etal. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142:687-698.
105. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294:1871-1875.
106. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;6:1191-1197.
107. Schwab JM, Chiang N, Arita M, etal. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature. 2007;447:869-874.
108. Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol. 2012;75:645-662.
109. MacLean CH, Mojica WA, Morton SC, etal. Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis. Evid Rep Technol Assess (Summ). 2004; Mar:1-4.
110. Geusens P, Wouters C, Nijs J, etal. Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. Arthritis Rheumatism. 1994;37:824-829.
111. James MJ, Cleland LG. Dietary n-3 fatty acids and therapy for rheumatoid arthritis. Semin Arthritis Rheum. 1997;27:85-97.
112. Broughton KS, Johnson CS, Pace BK, etal. Reduced asthma symptoms with n-3 fatty acid ingestion are related to 5-series leukotriene production. Am J Clin Nutr. 1997;65:1011-1017.
113. Turner D, Zlotkin SH, Shah PS, etal. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009;(1):CD006320.
114. Belluzzi A, Brignola C, Campieri M, etal. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med. 1996;334:1557-1560.
115. Salomon P, Kornbluth AA, Janowitz HD. Treatment of ulcerative colitis with fish oil n-3-omega-fatty acid: an open trial. J Clin Gastroenterol. 1990;12:157-161.
116. McCall TB, O'Leary D, Bloomfield J, etal. Therapeutic potential of fish oil in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 1989;3:415-424.
117. Mayser P, Mrowietz U, Arenberger P, etal. ω-3 Fatty acid-based lipid infusion in patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, multicenter trial. J Am Acad Dermatol. 1998;38:539-547.
118. Ziboh VA. Omega 3 polyunsaturated fatty acid constituents of fish oil and the management of skin inflammatory and scaly disorders. World Rev Nutr Diet. 1991;66:425-435.
119. MacLean CH, Newberry SJ, Mojica WA, etal. Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA. 2006;295:403-415.
120. Hooper L, Thompson RL, Harrison RA, etal. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ. 2006;332:752-760.
121. Zhang G, Panigrahy D, Mahakian LM, etal. Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A. 2013;110:6530-6535.
122. Arnold C, Markovic M, Blossey K, etal. Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of ω-3 fatty acids. J Biol Chem. 2010;285:32720-32733.
123. Cui PH, Petrovic N, Murray M. The omega-3 epoxide of eicosapentaenoic acid inhibits endothelial cell proliferation by p38 MAP kinase activation and cyclin D1/CDK4 down-regulation. Br J Pharmacol. 2011;162:1143-1155.
124. Lee M, Bae MA. Docosahexaenoic acid induces apoptosis in CYP2E1-containing HepG2 cells by activating the c-Jun N-terminal protein kinase related mitochondrial damage. J Nutr Biochem. 2007;18:348-354.
125. Panigrahy D, Kaipainen A, Greene ER, etal. Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev. 2010;29:723-735.
126. Chen JK, Capdevila J, Harris RC. Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis. Mol Cell Biol. 2001;21:6322-6331.
127. Jiang JG, Chen CL, Card JW, etal. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res. 2005;65:4707-4715.
128. Zhang W, Li P, Hu X, etal. Omega-3 polyunsaturated fatty acids in the brain: metabolism and neuroprotection. Front Biosci. 2011;16:2653-2670.
129. Luchtman DW, Song C. Cognitive enhancement by omega-3 fatty acids from child-hood to old age: findings from animal and clinical studies. Neuropharmacology. 2013;64:550-565.
130. SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res. 2005;24:87-138.
131. Fedorova I, Hussein N, Baumann MH, etal. An n-3 fatty acid deficiency impairs rat spatial learning in the Barnes maze. Behav Neurosci. 2009;123:196-205.
132. Lamptey MS, Walker BL. A possible essential role for dietary linolenic acid in the development of the young rat. J Nutr. 1976;106:86-93.
133. Garcia-Calatayud S, Redondo C, Martin E, etal. Brain docosahexaenoic acid status and learning in young rats submitted to dietary long-chain polyunsaturated fatty acid deficiency and supplementation limited to lactation. Pediatr Res. 2005;57(5 Pt 1):719-723.
134. Lim SY, Hoshiba J, Moriguchi T, etal. N-3 fatty acid deficiency induced by a modified artificial rearing method leads to poorer performance in spatial learning tasks. Pediatr Res. 2005;58:741-748.
135. Wainwright PE, Huang YS, Coscina DV, etal. Brain and behavioral effects of dietary n-3 deficiency in mice: a three generational study. Dev Psychobiol. 1994;27:467-487.
136. Yamamoto N, Saitoh M, Moriuchi A, etal. Effect of dietary alpha-linolenate/linoleate balance on brain lipid compositions and learning ability of rats. J Lipid Res. 1987;28:144-151.
137. Simmer K, Patole SK, Rao SC. Long-chain polyunsaturated fatty acid supplementation in infants born at term. Cochrane Database Syst Rev. 2011;(12):CD000376.
138. Meldrum SJ, Smith MA, Prescott SL, etal. Achieving definitive results in long-chain polyunsaturated fatty acid supplementation trials of term infants: factors for consideration. Nutr Rev. 2011;69:205-214.
139. Schulzke SM, Patole SK, Simmer K. Long-chain polyunsaturated fatty acid supplementation in preterm infants. Cochrane Database Syst Rev. 2011;(2):CD000375.
140. Alzheimer's Association. 2012 Alzhemier's disease facts and figures. Alzheimers Dement. 2012;8:131-168.
141. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr. 2000;71:S621-S629.
142. Neuringer M, Anderson GJ, Connor WE. The essentiality of n-3 fatty acids for the development and function of the retina and brain. Annu Rev Nutr. 1988;8:517-541.
143. Dyall SC, Michael-Titus AT. Neurological benefits of omega-3 fatty acids. Neuromolecular Med. 2008;10:219-235.
144. Tully AM, Roche HM, Doyle R, etal. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr. 2003;89:483-489.
145. Lin PY, Chiu CC, Huang SY, etal. A meta-analytic review of polyunsaturated fatty acid compositions in dementia. J Clin Psychiatry. 2012;73:1245-1254.
146. Tan ZS, Harris WS, Beiser AS, etal. Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging. Neurology. 2012;78:658-664.
147. Cole GM, Ma QL, Frautschy SA. Omega-3 fatty acids and dementia. Prostaglandins Leukot Essent Fatty Acids. 2009;81:213-221.
148. O'Brien DM, Kristal AR, Jeannet MA, etal. Red blood cell delta15N: a novel biomarker of dietary eicosapentaenoic acid and docosahexaenoic acid intake. Am J Clin Nutr. 2009;89:913-919.
149. Whalley LJ, Deary IJ, Starr JM, etal. n-3 Fatty acid erythrocyte membrane content, APOE varepsilon4, and cognitive variation: an observational follow-up study in late adulthood. Am J Clin Nutr. 2008;87:449-454.
150. Danthiir V, Burns NR, Nettelbeck T, etal. The older people, omega-3, and cognitive health (EPOCH) trial design and methodology: a randomised, double-blind, controlled trial investigating the effect of long-chain omega-3 fatty acids on cognitive ageing and wellbeing in cognitively healthy older adults. Nutr J. 2011;10:117.
151. Dangour AD, Allen E, Elbourne D, etal. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. Am J Clin Nutr. 2010;91:1725-1732.
152. Yurko-Mauro K, McCarthy D, Rom D, etal. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 2010;6:456-464.
153. Chiu CC, Su KP, Cheng TC, etal. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1538-1544.
154. van de Rest O, Geleijnse JM, Kok FJ, etal. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology. 2008;71:430-438.
155. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, etal. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol. 2006;63:1402-1408.
156. Andreeva VA, Kesse-Guyot E, Barberger-Gateau P, etal. Cognitive function after supplementation with B vitamins and long-chain omega-3 fatty acids: ancillary findings from the SU.FOL.OM3 randomized trial. Am J Clin Nutr. 2011;94:278-286.
157. Quinn JF, Raman R, Thomas RG, etal. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010;304:1903-1911.
158. Fontani G, Corradeschi F, Felici A, etal. Cognitive and physiological effects of omega-3 polyunsaturated fatty acid supplementation in healthy subjects. Eur J Clin Invest. 2005;35:691-699.
159. McNamara RK, Able J, Jandacek R, etal. Docosahexaenoic acid supplementation increases prefrontal cortex activation during sustained attention in healthy boys: a placebo-controlled, dose-ranging, functional magnetic resonance imaging study. Am J Clin Nutr. 2010;91:1060-1067.
160. Mazereeuw G, Lanctot KL, Chau SA, etal. Effects of ω-3 fatty acids on cognitive performance: a meta-analysis. Neurobiol Aging. 2012;33:1482.
161. IOM (Institute of Medicine). Seafood Choices: Balancing Benefits and Risks. Washington, DC: National Academy of Sciences, Institutes of Medicine; 2006.
162. US Department of Agriculture, Agricultural Research Service. USDA National Nutrient Database for Standard Reference, Release 25. 2012; Available at: http://www.ars.usda.gov/Services/docs.htm?docid=23601. Accessed 10 July 2012.
163. Racine RA, Deckelbaum RJ. Sources of the very-long-chain unsaturated omega-3 fatty acids: eicosapentaenoic acid and docosahexaenoic acid. Curr Opin Clin Nutr Metab Care. 2007;10:123-128.
164. Chee KM, Gong JX, Rees DM, etal. Fatty acid content of marine oil capsules. Lipids. 1990;25:523-528.
165. Whelan J, Jahns L, Kavanagh K. Docosahexaenoic acid: measurements in food and dietary exposure. Prostaglandins Leukot Essent Fatty Acids. 2009;81:133-136.
166. Gillies PJ, Harris WS, Kris-Etherton PM. Omega-3 fatty acids in food and pharma: the enabling role of biotechnology. Curr Atheroscler Rep. 2011;13:467-473.
167. Global Organization for EPA and DHA Omega-3. The global market for EPA/DHA omega-3 products. 2012; Rockville, MD: Packaged Facts.
168. Whelan J, Rust C. Innovative dietary sources of n-3 fatty acids. Annu Rev Nutr. 2006;26:75-103.
169. Mozaffarian D, Wu JH. (n-3) Fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary? J Nutr. 2012;142:S614-S625.
170. Davis BC, Kris-Etherton PM. Achieving optimal essential fatty acid status in vegetarians: current knowledge and practical implications. Am J Clin Nutr. 2003;78(Suppl 3):S640-S646.
171. Welch AA, Shakya-Shrestha S, Lentjes MA, etal. Dietary intake and status of n-3 polyunsaturated fatty acids in a population of fish-eating and non-fish-eating meat-eaters, vegetarians, and vegans and the product-precursor ratio [corrected] of alpha-linolenic acid to long-chain n-3 polyunsaturated fatty acids: results from the EPIC-Norfolk cohort [published correction appears in Am J Clin Nutr. 2011; 93:676]. Am J Clin Nutr. 2010;92:1040-1051.
172. Rosell MS, Lloyd-Wright Z, Appleby PN, etal. Long-chain n-3 polyunsaturated fatty acids in plasma in British meat-eating, vegetarian, and vegan men. Am J Clin Nutr. 2005;82:327-334.
173. Reddy S, Sanders TA, Obeid O. The influence of maternal vegetarian diet on essential fatty acid status of the newborn. Eur J Clin Nutr. 1994;48:358-368.
174. Harris WS, Pottala JV, Lacey SM, etal. Clinical correlates and heritability of erythrocyte eicosapentaenoic and docosahexaenoic acid content in the Framingham Heart Study. Atherosclerosis. 2012;225:425-431.
175. Madden J, Williams CM, Calder PC, etal. The impact of common gene variants on the response of biomarkers of cardiovascular disease (CVD) risk to increased fish oil fatty acids intakes. Annu Rev Nutr. 2011;31:203-234.
176. Lemaitre RN, Tanaka T, Tang W, etal. Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. PLoS Genet. 2011;7:e1002193.
177. Hodge AM, Simpson JA, Gibson RA, etal. Plasma phospholipid fatty acid composition as a biomarker of habitual dietary fat intake in an ethnically diverse cohort. Nutr Metab Cardiovasc Dis. 2007;17:415-426.
178. Knutsen SF, Fraser GE, Beeson WL, etal. Comparison of adipose tissue fatty acids with dietary fatty acids as measured by 24-hour recall and food frequency questionnaire in black and white Adventists: the Adventist Health Study. Ann Epidemiol. 2003;13:119-127.
179. Harris WS, von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med. 2004;39:212-220.
180. Block RC, Harris WS, Reid KJ, etal. EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. Atherosclerosis. 2008;197:821-828.
181. Harris WS, Sands SA, Windsor SL, etal. Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. Circulation. 2004;110:1645-1649.
182. Harris WS. Omega-3 fatty acids and cardiovascular disease: a case for omega-3 index as a new risk factor. Pharmacol Res. 2007;55:217-223.
183. US Food and Drug Administration. What you need to know about mercury in fish and shellfish. Washington, DC; US Food and Drug Administration; 2004.
184. Foran SE, Flood JG, Lewandrowski KB. Measurement of mercury levels in concentrated over-the-counter fish oil preparations: is fish oil healthier than fish? Arch Pathol Lab Med. 2003;127:1603-1605.
185. Wennberg M, Stromberg U, Bergdahl IA, etal. Myocardial infarction in relation to mercury and fatty acids from fish: a risk-benefit analysis based on pooled Finnish and Swedish data in men. Am J Clin Nutr. 2012;96:706-713.
186. Hughner RS, Maher JK, Childs NM. Review of food policy and consumer issues of mercury in fish. J Am Coll Nutr. 2008;27:185-194.
187. Cohen JT, Bellinger DC, Connor WE, etal. A quantitative risk-benefit analysis of changes in population fish consumption. Am J Prev Med. 2005;29:325-334.